Comparison of tofacitinib with NCES versus NCES alone for vitiligo
- Conditions
- Health Condition 1: O- Medical and SurgicalHealth Condition 2: L80- Vitiligo
- Registration Number
- CTRI/2024/01/061532
- Lead Sponsor
- All India Institute of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Adult ( >18 years) patients with non-segmental (generalized, acrofacial, focal) vitiligo clinically stable for <1 (3-12 months) year (VIDA Score +1 or +2)
1.Children, pregnant or lactating women with vitiligo
2.Patients with segmental vitiligo
3.Patients with vitiligo of clinical disease stability >1 year (VIDA score 0 or -1)
4.Patients with vitiligo of clinical disease stability < 3 months (VIDA score +3 or +4)
5.Patients with keloidal or bleeding tendency
6.Patients on topical treatment for last 2 weeks, and on phototherapy/systemic treatment for last 4 weeks
7.Patients with active tuberculosis / other systemic infection or any other contra-indication to tofacitinib
8.Patients with latent tuberculosis, who refuse prophylactic anti-tubercular treatment (Patients who have evidence of latent TB may be enrolled if they complete at least 4 weeks of appropriate treatment prior to randomization and agree to complete the remainder of treatment while in the trial)
9.Vitiligo patch <2.5cm2 or >100cm2
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method